Q3 2025 EPS Estimates for Biogen Inc. Reduced by Zacks Research (NASDAQ:BIIB)

Biogen Inc. (NASDAQ:BIIB) – Zacks Research reduced their Q3 2025 EPS estimates for shares of Biogen in a note issued to investors on Tuesday, April 2nd. Zacks Research analyst S. Ganoria now expects that the biotechnology company will earn $4.88 per share for the quarter, down from their prior estimate of $5.02. The consensus estimate for Biogen’s current full-year earnings is $15.48 per share. Zacks Research also issued estimates for Biogen’s FY2025 earnings at $17.74 EPS, Q1 2026 earnings at $3.95 EPS and FY2026 earnings at $17.96 EPS.

Several other research analysts have also recently weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $311.00 price target on shares of Biogen in a report on Tuesday, February 20th. BTIG Research reissued a “neutral” rating on shares of Biogen in a report on Sunday, January 7th. UBS Group lowered their price target on shares of Biogen from $276.00 to $250.00 and set a “neutral” rating on the stock in a report on Friday, February 16th. StockNews.com cut shares of Biogen from a “buy” rating to a “hold” rating in a report on Tuesday, February 20th. Finally, Needham & Company LLC lowered their target price on shares of Biogen from $305.00 to $300.00 and set a “buy” rating on the stock in a report on Tuesday, February 13th. Nine analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $302.52.

Biogen Stock Down 0.5 %

Shares of BIIB stock opened at $205.30 on Wednesday. The stock has a market cap of $29.84 billion, a price-to-earnings ratio of 25.73, a PEG ratio of 1.73 and a beta of -0.02. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.26 and a current ratio of 2.00. Biogen has a 52-week low of $205.22 and a 52-week high of $319.76. The firm’s 50-day moving average is $226.03 and its 200-day moving average is $240.51.

Biogen (NASDAQ:BIIB) last issued its earnings results on Tuesday, February 13th. The biotechnology company reported $2.95 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.18 by ($0.23). The firm had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.47 billion. Biogen had a net margin of 11.81% and a return on equity of 14.91%. During the same period in the previous year, the company posted $4.05 earnings per share.

Insider Transactions at Biogen

In other news, insider Priya Singhal sold 419 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $239.45, for a total value of $100,329.55. Following the completion of the transaction, the insider now owns 4,516 shares of the company’s stock, valued at $1,081,356.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Eric K. Rowinsky acquired 455 shares of the stock in a transaction dated Thursday, February 15th. The stock was bought at an average price of $222.54 per share, with a total value of $101,255.70. Following the completion of the purchase, the director now directly owns 20,629 shares of the company’s stock, valued at approximately $4,590,777.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Priya Singhal sold 419 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $239.45, for a total value of $100,329.55. Following the completion of the transaction, the insider now directly owns 4,516 shares of the company’s stock, valued at approximately $1,081,356.20. The disclosure for this sale can be found here. Over the last three months, insiders have sold 882 shares of company stock worth $202,030. Insiders own 0.60% of the company’s stock.

Institutional Trading of Biogen

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BIIB. Raymond James Trust N.A. increased its position in Biogen by 16.4% during the 1st quarter. Raymond James Trust N.A. now owns 3,294 shares of the biotechnology company’s stock valued at $693,000 after purchasing an additional 464 shares during the period. Cibc World Market Inc. increased its position in Biogen by 39.9% during the 1st quarter. Cibc World Market Inc. now owns 15,244 shares of the biotechnology company’s stock valued at $3,210,000 after purchasing an additional 4,349 shares during the period. Vanguard Group Inc. increased its position in Biogen by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 11,720,584 shares of the biotechnology company’s stock valued at $2,468,356,000 after purchasing an additional 183,285 shares during the period. Baird Financial Group Inc. boosted its holdings in shares of Biogen by 15.3% during the 1st quarter. Baird Financial Group Inc. now owns 89,722 shares of the biotechnology company’s stock worth $18,896,000 after buying an additional 11,882 shares in the last quarter. Finally, Brown Brothers Harriman & Co. boosted its holdings in shares of Biogen by 10.7% during the 1st quarter. Brown Brothers Harriman & Co. now owns 5,938 shares of the biotechnology company’s stock worth $1,251,000 after buying an additional 573 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.